Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

INSM

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

INSM

AI Research Report

Powered by Claude

Ready to analyze INSM

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Insmed Inc

Insmed Inc

Biotechnology·NASDAQ NMS - GLOBAL MARKET·US·IPO 1991-02-15

Analyst Consensus

Buy
Based on 26 analysts
Period: 2026-04-01
25 Buy (96%)1 Hold (4%)0 Sell (0%)
Rating Distribution
Strong Buy
9
Buy
16
Hold
1
Sell
0
Strong Sell
0
Trend
2026-04
25/1/0
2026-03
24/2/0
2026-02
25/2/0
2026-01
23/2/0
📅 Earnings in 21d (May 6)
  • Benzinga·13h ago

    RBC Capital Maintains Outperform on Insmed, Raises Price Target to $216

    RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $212 to $216.

  • Yahoo·1d ago

    Stanley Druckenmiller Made 1 Huge Bet That Still Looks Attractive Today and Cut 2 Top Positions

    Billionaire investor Stanley Druckenmiller is known for making bold moves when conviction is high, and his latest portfolio changes suggest he sees a major opportunity developing in one corner of the market. During the most recent quarter, Druckenmiller aggressively added to one large-cap tech position while reducing exposure to two major healthcare holdings that remain ... Stanley Druckenmiller Made 1 Huge Bet That Still Looks Attractive Today and Cut 2 Top Positions

  • Yahoo·3d ago

    Insmed (INSM): Top QQQ Stock to Buy Now

    Insmed Incorporated (NASDAQ:INSM) is one of the 9 Best QQQ Stocks to Buy Now. On April 07, Insmed announced that its Phase 2b CEDAR study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa/HS failed to meet its primary or secondary efficacy endpoints. In both the 10 mg and 40 mg treatment arms, […]

  • Yahoo·4d ago

    Here Are Friday’s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More

    Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on Thursday as mixed reports on the success of the ships passing through the Strait of Hormuz rolled in, stocks gained momentum as the ... Here Are Friday’s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More

  • Yahoo·4d ago

    Is It Too Late To Consider Insmed (INSM) After A 146% One Year Surge?

    Wondering whether Insmed at around US$159.59 is offering fair value or stretching expectations? This article walks through what the current price really implies for you as a shareholder or potential investor. The stock has had mixed recent returns, with about a 1.7% decline over the last 7 days, a 10.9% gain over the past month, a 9.9% decline year to date, and a 146.2% return over the last year. Recent coverage around Insmed has focused on its position in the biotech space and the market...

  • Yahoo·6d ago

    Insmed Incorporated (INSM): Billionaire Stan Druckenmiller Trims Stake

    Insmed Incorporated (NASDAQ:INSM) is one of Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential. Insmed Incorporated (NASDAQ:INSM) first appeared in the 13F portfolio of Duquesne Capital back in the second quarter of 2020. This position comprised 1.2 million shares and was sold off by the next quarter. A new position […]

  • Yahoo·6d ago

    Insmed Ends Brinsupri Development in Skin Disease Post Study Failure

    INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.

  • Yahoo·6d ago

    Latigo Biotherapeutics Appoints Sara M. Bonstein to its Board of Directors and as Audit Committee Chair

    THOUSAND OAKS, Calif., April 08, 2026--Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the appointment of Sara M. Bonstein as an independent director on the Company’s board of directors and as chairperson of the board’s audit committee. Ms. Bonstein is the chief financial officer of Insmed Incorporated (Insmed), and brings more than two decades of executive and financial leadership exp

  • View all news →
NASDAQ NMS - GLOBAL MARKETMarket closed
Insmed Inc
Biotechnology
$153.40
$2.26 (+1.50%)
Open
$152.21
Prev close
$151.14
Day range
$150.93 – $153.87
52W range
$61.48 – $212.75
Mkt cap
$33.07B
P/E
—
EPS
$-6.40
Beta
1.08

Fundamentals

Valuation
Market Cap
$33.07B
P/E (TTM)
—S&P avg ~22
P/S (TTM)
54.04S&P avg ~2.8
P/B
50.23S&P avg ~4.5
P/FCF
—S&P avg ~26
EPS (TTM)
$-6.40
Book/sh
$3.45
Cash/sh
$6.67
Profitability
Gross Margin
79.73%avg ~45%
Operating Margin
-205.59%avg ~15%
Net Margin
-210.54%avg ~12%
ROE
-168.36%avg ~18%
ROA
-57.33%avg ~7%
ROI
-78.43%
Payout Ratio
—
FCF/sh
—
Growth & Health
Rev Growth YoY
66.73%
Rev Growth 5Y
29.83%
EPS Growth YoY
—
EPS Growth 5Y
—
Current Ratio
—
Quick Ratio
3.35
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
1.08
52W High
$212.75
52W Low
$61.48
Avg Vol (10D)
2.53M
Avg Vol (3M)
2.78M
Div Yield
—
Div/sh (TTM)
—
Analyst
Buy (26)
Price Performance
5D-7.29%
MTD-7.57%
3M-11.24%
6M-4.51%
YTD-13.16%
1Y+133.20%

Factor Grades

View details →
C-
Overall score: 45/100
F
Valuation
A
Growth
D
Profitability
D+
Momentum
C
Financial Health

Recent insider activity

View all →
  • 4FORM 4
    7d ago
  • 4FORM 4
    12d ago
  • 4FORM 4
    15d ago
  • 4FORM 4
    26d ago
  • 4FORM 4
    Mar 5